Status:
RECRUITING
Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain
Lead Sponsor:
Erchonia Corporation
Conditions:
Neuropathy
Neuropathy;Peripheral
Eligibility:
All Genders
22+ years
Phase:
NA
Brief Summary
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temp...
Detailed Description
This clinical study is a single-arm, active treatment group only, non-inferiority prospective design to evaluate the efficacy of the Erchonia® EVRL™ for prescription home use application in providing ...
Eligibility Criteria
Inclusion
- Previously diagnosed with idiopathic peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months.
- Over the age of 22 years of age
- Able to read and write English
- Constant feet pain on-going over at least the past 3 months
- Subjects using analgesics (pain medication) must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to study enrollment; and be willing and able to not have planned upward dose titration of analgesics during the study period. Decreasing frequency of analgesic use during the study is permitted. Cannabis prescribed for medicinal purposes qualifies as an analgesic in this context
- Willing and able to refrain from engaging in any non-study therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy, hot or cold packs, and alternative therapies such as chiropractic care and acupuncture
- Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded
- Subject's degree of foot pain on the 0-100 VAS, with "0" being no pain and "100" being worst pain imaginable, is 50 or greater
Exclusion
- Diabetic, referred to as having hemoglobin A1c (HbA1C) of 6.5% or higher
- Previously diagnosed with any definitive (i.e. not idiopathic) cause of peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months, such as diabetes, injury, infection, toxins and poisons, alcoholism, medications such as chemotherapy, autoimmune disorders, etc..
- Pregnant or possibly pregnant, breastfeeding, or planning pregnancy during the intended course of study participation
- Open wounds (sores, cuts, ulcers, etc.) on or around the treatment area on the feet
- Cancerous growths or lesions on or around the treatment area on the feet
- Difficulty with hand dexterity sufficient to negatively impact the ability to administer treatments with the laser such as from severe arthritis in the hands, Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 16 2027
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06912646
Start Date
May 1 2025
End Date
June 16 2027
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Franco & Co
Miramar, Florida, United States, 33025